PF-08046054 by Pfizer for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

PF-08046054 is under clinical development by Pfizer and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Sofinnova details European investment strategy; C4’s new PhI data; Coya closes $26M placement

Sofinnova Partners outlines European investment strategy: The venture capital firm aims to launch and accelerate biotech startups in Europe using a similar model to BiovelocITA,

December 14, 2023

CBER chief floats rare disease hub to better communicate across centers

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 21, 2024

Life sciences investor Dimension seeks to raise $500M second fund

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.